Methods and compositions are provided herein whereby a patient with cancer is administered a treatment comprising NK cells in order to induce expression of MHC-I in a tumor, and wherein subsequent treatment with T cells effectively targets tumor associated antigens and neoepitopes presented by newly expressed MHC-I in said tumor cells.
Systems, apparatus, and methods of rendering content based on a control point of a camera device are disclosed. In an example, a marker is attached to the camera device and its pose is tracked over time. Based on a camera model of the camera device, an offset between the marker and the control point is determined. The tracked pose of the marker can be translated and/or rotated according to the offset to estimate a pose of the control point. The rendering of the content is adjusted over time based on the estimated poses of the control point. Upon presentation of the content in a real-world space (e.g., on a display assembly located therein), the camera device can capture the content along with other objects of the real-world space and generate a video stream thereof.
Systems, apparatus, and methods for rendering content based on display assembly pose are disclosed. In an example, motion capture data of a display of a plurality of displays is received, the display moving from a first physical pose to a second physical pose. The motion capture data is processed to determine the coordinates of the second physical pose. A transformation of the second physical pose of the display to a virtual pose of the display is generated. A virtual model of the plurality of displays is updated, the virtual model comprising the virtual pose of the display. The content is rendered on the updated virtual model.
G06T 19/20 - Transformation de modèles ou d'images tridimensionnels [3D] pour infographie Édition d'images tridimensionnelles [3D], p.ex. modification de formes ou de couleurs, alignement d'objets ou positionnements de parties
G06F 3/14 - Sortie numérique vers un dispositif de visualisation
4.
DISTRIBUTED COMMAND EXECUTION IN MULTI-LOCATION STUDIO ENVIRONMENTS
A content production management system within a distributed studio environment includes a command interface module and a command queue management module. The command interface module is configured to render a user interface for a set of content production entities associated with a set of content production volumes within the distributed studio environment. The command queue management module, upon execution of software instructions, is configured to perform the operations of receiving, from the command interface module, a command targeting a target content production entity, assigning a synchronized execution time to the command, enqueueing the command into a command queue associated with the target content production entity according to the synchronized execution time, and enabling the target content production entity to execute the command from the command queue according to the synchronized execution time.
G06Q 10/06 - Ressources, gestion de tâches, des ressources humaines ou de projets; Planification d’entreprise ou d’organisation; Modélisation d’entreprise ou d’organisation
5.
GRAPHENE NANOPLATELET BATTERIES, APPARATUS, AND COMPOSITIONS
Devices and methods are presented that comprise graphene platelets with controlled dimension and high carbon to oxygen ratio, and that further include a heteroatom or heteroionic species, an alkylammonium polysulfide, or both, preferably non-covalently bound to the graphene platelets. Such compositions have significantly improved conductive properties as opposed to unmodified graphene platelets and can be easily produced at mass quantities and low cost.
H01M 4/583 - Matériau carboné, p.ex. composés au graphite d'intercalation ou CFx
H01M 4/133 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de matériau carboné, p.ex. composés d'intercalation du graphite ou CFx
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/86 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes inertes ayant une activité catalytique, p.ex. pour piles à combustible
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
H01M 50/409 - Séparateurs, membranes ou diaphragmes caractérisés par le matériau
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
6.
METHODS AND SYSTEMS FOR PRODUCING A PROTEIN OF INTEREST IN A PLANT
Methods and systems for producing a protein of interest within a plant or a portion of a plant are provided herein. The method includes introducing one or more nucleic acid into the plant or the portion of the plant, the nucleic acid including a nucleotide sequence encoding the protein of interest and incubating the plant or the portion of the plant under conditions that permit the expression of the nucleotide sequence encoding the protein of interest. The method also includes adding a medium amendment including a calcium carbonate source, such as aragonite, to a medium environment of the plant.
Vaccine compositions are provided that comprise a lyophilized, adenovirus-based expression vector, and a stabilizing compound, such as such as aragonite. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.
A vaccine composition to induce immunity against a coronavirus in a subject comprises a recombinant nucleic acid that encodes N-ETSD, a modified nucleocapsid protein that includes an endosomal targeting sequence, and/or that encodes S-Fusion, a modified spike protein that has improved surface expression. The vaccine may be formulated as a recombinant nucleic acid, recombinant yeast, and/or recombinant virus such as an adenovirus and can be administered via injection and/or mucosal delivery.
Compositions and methods are presented in which aragonite, and especially oolitic aragonite particles are used as infill material in an artificial turf structure or as sub-growth substrate for natural grass. Advantageously, oolitic aragonite particles provide: a superior microporous surface for effective water saturation to impart thermal control and environmental compatibility; ammonia neutralization of urine by reducing urea hydrolysis with the free calcium presented in the aragonite particles; and aragonite particle uniformity allowing for reduced compaction and desirable water draining.
B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
10.
METHODS OF PREPARING CANCER TREATMENTS AND METHODS OF TREATING CANCER
Methods for preparing antigen-loaded dendritic cells (DCs) for treatment of cancer in a subject are provided, using an electroporation apparatus having an electroporation chamber including an upper electrode, a lower electrode and a path defined in the electroporation chamber. The electroporation apparatus includes a first input allowing passage of DCs into the electroporation chamber and a first output allowing passage of antigen-loaded DCs from the electroporation chamber. The first input and the first output are separated by an offset distance. Methods of treating cancer by administering antigen-loaded DCs are also provided.
Compositions, methods, and uses of aragonite biobased polymer plastic compositions are presented having increased strength and stiffness as well as improved recyclability and/or biodegradability. The aragonite biobased plastic compositions include aragonite blended in a dispersion with a biobased polymer and optionally includes a petroleum-based polymer and/or a compatibilizer.
C08L 23/26 - Compositions contenant des homopolymères ou des copolymères d'hydrocarbures aliphatiques non saturés ne possédant qu'une seule liaison double carbone-carbone; Compositions contenant des dérivés de tels polymères modifiées par post-traitement chimique
C08L 77/00 - Compositions contenant des polyamides obtenus par des réactions créant une liaison amide carboxylique dans la chaîne principale; Compositions contenant des dérivés de tels polymères
12.
NOGAPENDEKIN ALFA-INBAKICEPT FOR IMMUNE STIMULANT THERAPIES AND TREATMENT OF VIRAL INFECTIONS
Pharmaceutical compositions comprising an IL-15 agonist or derivative thereof, such as nogapendekin alfa-inbakicept (NAI), are provided herein for enhancing immunity and for inhibiting viral infections. The IL-15 agonist or derivative thereof may be used to increase proliferative capacity and/or cytotoxicity of various immune competent cells, and especially NK and cytotoxic T cells in healthy individuals. The IL-15 agonist or derivative thereof may be used alone or in combination with one or more other therapeutic agents, such as in conjunction with a vaccine.
Compositions, methods, and uses of calcium carbonate-based composition are presented. The calcium carbonate-based composition includes a plurality of restructured calcium carbonate particles that has an average size of equal or less than 10 microns in diameter. Preferably, the calcium carbonate-based composition is generated by unstructuring the aragonite using an acid and a chelator and recrystallizing the unstructured aragonite in a customized form. Exemplary aragonite-based compositions include pavement compositions.
Techniques including data collection, organization and usage are provided, including in connection with computer-based gaming. Methods and systems are provided for establishing a set of data chronicling at least a portion of a duration of a computer-based gaming event that includes at least one user engaging in gaming using a computer or a computer-based device. Event data is obtained for chronicling chronologically ordered in-game events. Hardware and software related data is obtained that relates to the computer or the computer-based device and is relevant to the chronicling of the portion of the gaming event. Utilizing a distributed ledger technology or blockchain, the event data and the hardware and software related data are recorded in establishing the set of data chronicling at least a portion of the duration of the gaming event.
A63F 13/77 - Aspects de sécurité ou de gestion du jeu incluant les données relatives aux dispositifs ou aux serveurs de jeu, p.ex. données de configuration, version du logiciel ou quantité de mémoire
A63F 13/49 - Sauvegarde de l’état du jeu; Pause ou fin du jeu
H04L 29/08 - Procédure de commande de la transmission, p.ex. procédure de commande du niveau de la liaison
A63F 13/35 - Dispositions d’interconnexion entre des serveurs et des dispositifs de jeu; Dispositions d’interconnexion entre des dispositifs de jeu; Dispositions d’interconnexion entre des serveurs de jeu - Détails des serveurs de jeu
A method includes accessing a structured content item from a first database and event data from a second database, the event data including sets of event attributes in a multi-dimensional namespace and associated with a respective point in time; determining a relevancy profile characterizing a metric of relevancy of the structured content item over a respective time interval, the metric of relevancy including a distance in the multi-dimensional namespace between attributes associated with the structured content and the sets of event attributes; generating, using the relevancy profile, second digital content including a subset of the structured content item; and providing the second digital content for rendering on a device. Related apparatus, systems, techniques and articles are also described.
G06F 7/00 - Procédés ou dispositions pour le traitement de données en agissant sur l'ordre ou le contenu des données maniées
G06F 17/30 - Recherche documentaire; Structures de bases de données à cet effet
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
Compositions, methods, and uses of an alpha emitter are provided in which the alpha emitter is coupled to carrier protein via a cleavable coupling moiety. The coupling moiety is preferably cleavable in an acidic tumor microenvironment, and as such will enrich the alpha emitter upon cleavage within the tumor microenvironment.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Methods for analyzing omics data and using the omics data to determine genetic distances and/or difference scores among a plurality of biological samples to so further determine the homogeneity of a group having a plurality of biological samples and/or exclude an individual biological sample from a group of biological samples as an outlier are presented. In preferred methods, a plurality of local differential string sets among the plurality of sequence strings is generated using a plurality of local alignments. The local different string is an indicative of genetic difference between one sequence string and one of the rests of the sequence strings among the plurality of sequence strings. From the plurality of local differential string sets, a plurality of difference scores among the plurality of sequence strings can be determined.
Compositions, methods, and uses of recombinant immunoglobulin proteins, recombinant immunoglobulin protein complexes, carrier protein complexes, and a pharmaceutical composition including one or more of those to increase immune therapy effectiveness are presented. Preferred protein and protein complex comprise one or more functional moieties that includes a binding motif to a tumor-associated antigen, a T-cell activating molecule, and a chemokine. In some embodiments, the pharmaceutical composition includes two or more protein complexes, which are functionally distinct from each other. In other embodiments, the pharmaceutical composition includes a genetically-engineered microorganism including a first tumor-associated antigen and a T-cell activating molecule, a recombinant immunoglobulin protein complex, and a chemokine.
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/00 - Préparations médicinales contenant des peptides
Techniques are provided for multi-modal sensitive recognition. A digital data set for an object is obtained according to a modality, where the digital data set includes digital representations of the object at different values of a dimension of relevance of the modality. A reference location associated with the object is identified. A modal descriptor is derived for the modality according to an implementation of a multi-modal recognition algorithm by deriving a set of feature descriptors for the reference location and at the different values of the corresponding dimension of relevance, calculating a set of differences between the feature descriptors in the set of feature descriptors, and aggregating the set of differences into the modal descriptor. A device is then configured to initiate an action as a function of the modal descriptor.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G06K 9/46 - Extraction d'éléments ou de caractéristiques de l'image
20.
BAM SIGNATURES FROM LIQUID AND SOLID TUMORS AND USES THEREFOR
Treatment of a patient diagnosed with cancer is monitored by comparing sequence data from liquid biopsies obtained during and/or after treatment with tumor and patient specific sequence data from a solid tumor obtained prior to treatment.
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Compositions, methods, and uses of recombinant calreticulin protein that is modified to be expressed on the cell surface are presented. Preferably, the recombinant calreticulin protein is presented on the antigen presenting cell surface with a tumor associated protein to increase immunogenicity of the tumor cell in the tumor microenvironment.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
Methods and compositions for generating enhanced immune responses using adenovirus vectors that encode for an antigen and calreticulin, which serves as an immunologic adjuvant.
Chimeric molecules and molecule complexes that include an Fc portion of an antibody and an immunomodulatory portion and uses thereof are contemplated. Typically, the chimeric molecule comprises at least two immune effectors, for example, IL-15 antagonist and PD-L1 binding domain. It is contemplated that a tumor cell or an immune competent cell can be exposed to the chimeric molecule to increase the effectiveness tumor cell lysis via an antibody-dependent cell-mediated cytotoxicity.
C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
An immune gene expression signature is associated with favorable clinical features in Treg –enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.
G16B 25/10 - Profilage de l’expression de gènes ou de protéines; Estimation ou normalisation de ratio d’expression
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
Systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor are disclosed. The methods use sequence information of the neoepitope.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
Contemplated systems and methods use high-accuracy in silico HLA analysis to so establish a transplant match database suitable for transplantation, and particularly stem cell and solid organ transplant.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 25/00 - TIC spécialement adaptées à l’hybridation; TIC spécialement adaptées à l’expression de gènes ou de protéines
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
28.
CIRCULATING TUMOR CELL ENRICHMENT USING NEOEPITOPES
in silicoin silico analysis of the tumor genome and RNA or phage display, and can be used to isolate cellular components, and especially circulating tumor cells, metastatic cells, and/or exosomes and microvesicles.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
29.
MODELING miRNA INDUCED SILENCING IN BREAST CANCER WITH PARADIGM
A probabilistic graphical pathway model is modified to include miRNA regulation by adding RISC as a regulatory factor. Most preferably, the pathway model is built using factor graphs, and the RISC includes DICER, TARBP2, and AGO2 or AGO1/3/4. So constructed pathway models can be used to infer RISC activity, which can be associated with various clinically relevant parameters to build various predictors or diagnostic tests.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G06F 19/10 - Bio-informatique, c. à d. procédés ou systèmes pour le traitement de données génétiques ou se rapportant aux protéines en biologie moléculaire informatique (procédés in silico de criblage de bibliothèques chimiques virtuelles C40B 30/02;procédés mathématiques ou in silicio de création de bibliothèques chimiques virtuelles C40B 50/02)
G06F 19/12 - pour la modélisation ou la simulation en biologie des systèmes, p.ex. modèles probabilistes ou dynamiques, réseaux régulateurs de gènes, réseaux d'interaction protéique ou réseaux métaboliques
G06F 19/18 - pour la génomique ou la protéomique fonctionnelle, p.ex. associations génotype-phénotype, déséquilibre de liaison, mutagénèse, génotypage ou annotation génomique, interactions protéines-protéines ou interactions protéines-acides nucléiques
G06F 19/26 - pour la visualisation de données, p.ex. production de graphiques, affichage de cartes ou de réseaux ou autres représentations visuelles
30.
MAXIMIZING T-CELL MEMORY AND COMPOSITIONS AND METHODS THEREFOR
Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
Contemplated compositions and methods take advantage of one or more surface markers on cancer stem cell that are associated with self-protection of tumor cells. Such surface markers are specifically targeted to guide a cell-based cancer treatment, and especially hypoxia resistant NK cells and radiotherapeutics directly to the cancer stem cell. In addition, immune suppression can be counteracted using various inhibitors, while immune response may be further augmented using certain immune stimulatory agents.
Contemplated compositions and methods sensitize tumor cells to a cancer treatment regimen, including chemotherapy, radiation therapy, and immune therapy by preventing EMT (epidermal to mesenchymal transition) of the tumor cell, or by reversing the tumor cell from a mesenchymal to an epidermal state. Thusly sensitized cells are then subjected to the cancer treatment regimen.
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
Contemplated systems and methods verify a patient' s likely immune response to a neoepitope -based treatment by (a) assessing whether or not the patient's immune system is ready to mount an immune response, (b) determining prior response by patient immune- competent cells, and (c) determining the capability for patient immune-competent cells to respond to a future immune stimulus.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
34.
METHODS AND ARTIFICIAL TUMORS FOR VALIDATING AN ANTITUMOR IMMUNE RESPONSE
The invention provides methods for validating an antitumor response by growing and maintaining artificial 3D tumors under conditions that replicate the microenvironment of the naturally occurring parent tumor as found, in situ, in a subject diagnosed with a tumor or cancer. The artificial 3D tumors are obtained from the subject and once established are tested for susceptibility to proposed anticancer treatments, such as treatments personalized to the subject.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
Contemplated compositions and methods comprise chimeric molecule complexes that advantageously provide activating signaling to immune competent cells when bound to ALL cells. Furthermore, chimeric molecule complexes include an Fc portion to extend serum half live time and facilitate purification.
Systems and methods for predicting an immune response against a tumor in a patient having the tumor are provided. The relative mass or changes of mass of tumor cells or immune cell in the tumor can be ex vivo observed, and an immune status of the tumor can be determined based on the mass of tumor cells or immune cell. The immune status can provide a guidance to predict the immune response against the tumor in the patient.tumor in the patient.
G01N 33/483 - Analyse physique de matériau biologique
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 21/45 - Réfringence; Propriétés liées à la phase, p.ex. longueur du chemin optique en utilisant les méthodes de Schlieren
37.
METHOD OF VALIDATING THE TRIGGERING OF AN IMMUNE RESPONSE TO A NEOEPITOPE OF A TUMOR WITH T-CELLS
The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.
Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
39.
METHODS AND SYSTEMS FOR PREDICTING DNA ACCESSIBILITY IN THE PAN-CANCER GENOME
Techniques are provided for predicting DNA accessibility. DNase-seq data files and RNA-seq data files for a plurality of cell types are paired by assigning DNase-seq data files to RNA-seq data files that are at least within a same biotype. A neural network is configured to be trained using batches of the paired data files, where configuring the neural network comprises configuring convolutional layers to process a first input comprising DNA sequence data from a paired data file to generate a convolved output, and fully connected layers following the convolutional layers to concatenate the convolved output with a second input comprising gene expression levels derived from RNA-seq data from the paired data file and process the concatenation to generate a DNA accessibility prediction output. The trained neural network is used to predict DNA accessibility in a genomic sample input comprising RNA-seq data and whole genome sequencing for a new cell type.
G06F 19/24 - pour l'apprentissage automatique, l'exploration de données ou les bio statistiques, p.ex. détection de motifs, extraction de connaissances, extraction de règles, corrélation, agrégation ou classification
G06F 19/12 - pour la modélisation ou la simulation en biologie des systèmes, p.ex. modèles probabilistes ou dynamiques, réseaux régulateurs de gènes, réseaux d'interaction protéique ou réseaux métaboliques
G06F 19/26 - pour la visualisation de données, p.ex. production de graphiques, affichage de cartes ou de réseaux ou autres représentations visuelles
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention provides a method of validating a predicted pathway activity of a pathway in a solid tumor of a subject, with a digital computer, the method comprising : a) obtaining a tumor associated sample from the subject; b) obtaining omics data from the tumor associated sample obtained in (a); c) applying the omics data obtained in (b) to a digital computer programmed with a pathway analysis engine configured to generate predicted tumor cell pathway activities in silico, to provide a prediction of one or more pharmaceutically active anticancer compounds effective for treating the subject's tumor; d) obtaining enriched viable tumor cells from the subject, and interrogating the enriched viable tumor cells with at least one pharmaceutically active compound known to interact with a pathway element of one or more of the pathways predicted by (c), to measure anticancer activity of the at least one pharmaceutically active compound with respect to the subject's enriched viable tumor cells.
G06F 19/12 - pour la modélisation ou la simulation en biologie des systèmes, p.ex. modèles probabilistes ou dynamiques, réseaux régulateurs de gènes, réseaux d'interaction protéique ou réseaux métaboliques
Contemplated compositions and methods generate a durable immune synapse and so lead to activated T-cells and memory T-cell formation by use of selected co-stimulatory receptors and their ligands in conjunction with selected neoepitopes. Moreover, immune competent cells are attracted into a tumor microenvironment after activation of the T-cells using hybrid or chimeric binding proteins that comprise a chemokine portion and that target components of necrotic cells.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
42.
IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS
A chimeric immune modulator is provided, that comprises a first immune modulating portion and a second portion, wherein the second portion comprises an epitope; and the modulating portion and the second portion of the moiety are coupled together via a linker. Methods of making and using the chimeric immune modulator are also provided. Methods of making and using the chimeric immune modulator are also provided.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
43.
AVATAR DENDRITIC CELLS: THE NEOANTIGEN NATURAL KILLER T-CELL CHEMO IMMUNO RADIATION COMPOSITION INDUCING IMMUNOGENIC CELL DEATH
Contemplated compositions and methods counteract evasive measures of a tumor by rendering access to the tumor microenvironment, tagging the tumor microenvironment with chemoattractant and/or cytokines, delivering or facilitating a cell-based therapy in the tumor microenvironment while providing inhibition of immune suppressor cells in the tumor microenvironment.
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A network provisioning device comprises an administrative interface for instantiating a virtual circuit definition to communicatively couple a set of endpoint devices in a network fabric, and a virtual circuit constructor. The virtual circuit constructor converts the virtual circuit definition into Layer-2 provisioning commands, selects a target set of networking nodes that connect to the endpoint devices, and transmits the Layer-2 provisioning commands to the target set of networking nodes. VXLAN virtual circuit provisioning in the target set of networking nodes establishes a VXLAN circuit to communicatively couple the endpoint devices.
Systems and methods for tracking samples via sample tracking chains are presented. Sample tracking chains represent digital data structures instantiated according to intrinsic properties of a sample. Each link in the chain is a block of data representing an observed intrinsic state of the sample and is linked at least to a previous block representing a previous state. The sample tracking chain and blocks can be indexed for later retrieval by the intrinsic properties of the corresponding sample's state. The sample tracking chain can take the form of a blockchain possibly stored as part of a private or public distributed ledger. Disclosed sample tracking chains provide a full life cycle audit trail for sample processing.
Immunotherapeutic methods and compositions are contemplated where one or more neoepitopes and/or tumor associated antigens are produced in, or delivered to dendritic cells, and in which so modified dendritic cells are co-cultured with immune competent cells of a patient, preferably in the presence of stimulatory signals. Cells are then transfused to the patient that has preferably undergone immune checkpoint inhibition treatment.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
47.
DISTRIBUTED MACHINE LEARNING SYSTEMS, APPARATUS, AND METHODS
A distributed, online machine learning system is presented. Contemplated systems include many private data servers, each having local private data. Researchers can request that relevant private data servers train implementations of machine learning algorithms on their local private data without requiring de-identification of the private data or without exposing the private data to unauthorized computing systems. The private data servers also generate synthetic or proxy data according to the data distributions of the actual data. The servers then use the proxy data to train proxy models. When the proxy models are sufficiently similar to the trained actual models, the proxy data, proxy model parameters, or other learned knowledge can be transmitted to one or more non-private computing devices. The learned knowledge from many private data servers can then be aggregated into one or more trained global models without exposing private data.
Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
Systems and methods of monitoring treatment of a patient use information gained from exosomes, wherein the treatment target that was identified from a tumor is followed in exosomes in a biological fluid outside the tumor.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
51.
NEOEPITOPE VACCINE COMPOSITIONS AND METHODS OF USE THEREOF
In certain embodiments, methods and compositions are provided for generating immune responses against tumor neo-antigens or neo-epitopes. In particular embodiments there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor neo-antigens and neo-epitopes that allow for vaccinations in individuals with preexisting immunity to adenovirus. In additional embodiments, methods and compositions are provided for the treatment of cancer using immunotherapy based on recombinant adenovirus-based vectors combined with engineered natural killer cells. In some embodiments, the methods and compositions further comprises a nucleic acid encoding for an immunological fusion partner.
Methods, systems, and articles of manufacture to improve image recognition searching are disclosed. In some embodiments, a first document image of a known object is used to generate one or more other document images of the same object by applying one or more techniques for synthetically generating images. The synthetically generated images correspond to different variations in conditions under which a potential query image might be captured. Extracted features from an initial image of a known object and features extracted from the one or more synthetically generated images are stored, along with their locations, as part of a common model of the known object. In other embodiments, image recognition search effectiveness is improved by transforming the location of features of multiple images of a same known object into a common coordinate system. This can enhance the accuracy of certain aspects of existing image search/recognition techniques including, for example, geometric verification.
Ex vivo determination of increased tumor immunogenicity of a tumor biopsy is used as a guide to identify immunotherapy of a tumor in a patient. Most preferably, the ex vivo tests will include exposure of biopsy samples to stress conditions to produce pretreated tumor cells that are then assayed with immune competent cells for increased activation or activity. Test conditions include exposure of the biopsy samples to immune stimulatory compositions, antibodies against neoepitopes, and/or modified cells, and an increase of immunogenicity is preferably determined by their exposure to T cells and/or NK cells.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
54.
SUBCUTANEOUS DELIVERY OF ADENOVIRUS WITH DUAL TARGETING
Immunotherapeutic methods and compositions are contemplated in which neoepitopes and/or tumor associated antigens are delivered to dendritic cells via an adenoviral expression system that targets MHC-I and/or MHC-II presentation systems and that further provides one or more recombinant peptides to stimulate T cell activation and interfere with checkpoint inhibition. Treatment is further supported by transfusion of NK cells, which may be modified to have a high affinity CD 16 receptor and/or a chimeric antigen receptor that binds to one or more neoepitopes and/or tumor associated antigens.
Systems and methods are presented that allow for selection of tumor neoepitopes that are filtered for various criteria. In particularly contemplated aspects, filtering includes a step in which the mutation leading to the neoepitope is ascertained as being located in a cancer driver gene.
G06F 19/18 - pour la génomique ou la protéomique fonctionnelle, p.ex. associations génotype-phénotype, déséquilibre de liaison, mutagénèse, génotypage ou annotation génomique, interactions protéines-protéines ou interactions protéines-acides nucléiques
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
56.
COMPOSITIONS AND METHODS FOR RECOMBINANT CXADR EXPRESSION
Recombinant expression of CXADR in a cell, and especially an immune competent cell is employed to enable or improve gene delivery to the cell by an adenovirus. In particularly preferred aspects, the immune competent cell is a an NK cell, a T-cell, a B-cell, a macrophage, or a dendritic cell, and the gene delivery comprises a recombinant nucleic acid encoding a disease-specific antigen, such as a patient specific neoepitope or a tumor associated antigen.
NK cell based cancer immunotherapy, and particularly genetically modified NK92 cell-based immunotherapy is enhanced by expression CXCL12 and/or by suppression or deletion of CXCR4 in the natural killer cells to so reduce aggregation, rejection, and/or fratricide of the natural killer cells.
Contemplated immunotherapies include co-administration of an activated NK cell that is further genetically modified and a cancer therapeutic agent. In preferred embodiments, activated NK cells are further modified to taNK cells, which include a chimeric antigen receptor (CAR) with affinity for a cancer specific antigen, a cancer associated antigen, or a tumor specific antigen. Activated NK cells can also be further genetically modified to include high affinity Fc receptor CD16a (V158). Appropriate cancer therapeutic agents include chemotherapeutic drugs (e.g., nant-paclitaxel) or cancer targeted antibodies (e.g., trastuzumab).
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à quatre chaînons, p.ex. taxol
59.
IMPROVED COMPOSITIONS AND METHODS FOR VIRAL DELIVERY OF NEOEPITOPES AND USES THEREOF
Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor.
Various protein markers can be used as post-treatment relapse predictors in HER2 positive breast cancer. Notably, these markers appear to be independent of the size of the tumor, metastasis status, grade, and hormone receptor status. In addition, HER2 quantities were in large part not correlated with likelihood of relapse.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à quatre chaînons, p.ex. taxol
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
61.
ACTIVATION OF IMMUNE-RELATED SIGNALLING PATHWAYS IN CELLS VIA OPTOFECTION
Systems and methods of inducing large-scale optical transfection and generation of an immune response in target cells are presented. In preferred aspects large-scale optofection uses nanoparticles with target specific affinity moieties to generate cavitation events proximal to the cell membrane of cells to which the nanoparticles are attached, and suspended and/or dissolved cargo is so provided access into the cell. Notably, cells can be transfected in very large quantities at high viability, with the transfected cells exhibiting up-regulated immune responses.
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p.ex. magnétisme, ondes sonores
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p.ex. par magnétisme, par des ondes sonores
62.
HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS
Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.
C07D 491/052 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à six chaînons
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/4355 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'oxygène comme hétéro-atome du cycle
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p.ex. ticlopidine
63.
PATIENT TREATMENT VIA TERATOGENIC PHARMACEUTICAL COMPOUNDS
Compositions and methods for treatment of a condition associated with disease stem cells, and especially cancer stem cells are disclosed. In one aspect, a patient is treated with a stem cell differentiating agent and/or teratogenic pharmaceutical compound to induce one or more destructive pathways in the disease stem cells. Most typically, the destructive pathways include apoptotic pathways, necrotic pathways, and autophagy pathways.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p.ex. quinones, vitamine K1, anthraline
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/4725 - Isoquinoléines non condensées, p.ex. papavérine contenant d'autres hétérocycles
Various devices, systems, structures and methods are disclosed related to securely authorizing a transaction by synchronizing digital genomic data with associated synthetic genomic variants. An embodiment of the present invention utilizes digital genomic data associated with an entity, such as a person, who may utilize a genome-based security device to complete a transaction. In one embodiment, a person may use a genome-based security device to communicate with an external device over a wireless or other communication interface, synchronize digital genomic data and an associated synthetic variant received from the external device with digital genomic data and associated synthetic variant stored on the genome-based security device.
H04L 9/32 - Dispositions pour les communications secrètes ou protégées; Protocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
G06F 19/22 - pour la comparaison de séquences impliquant des nucléotides ou des acides aminés, p.ex. recherche d'homologie, identification de motifs ou de polymorphismes de nucléotides simples [SNP] ou alignement de séquences
67.
SYSTEMS AND METHODS FOR COMPREHENSIVE ANALYSIS OF MOLECULAR PROFILES ACROSS MULTIPLE TUMOR AND GERMLINE EXOMES
Omics patient data are analyzed using sequences or diff objects of tumor and matched normal tissue to identify patient and disease specific mutations, using transcriptomic data to identify expression levels of the mutated genes, and pathway analysis based on the so obtained omic data to identify specific pathway characteristics for the diseased tissue. Most notably, many different tumors have shared pathway characteristics, and identification of a pathway characteristic of a tumor may thus indicate effective treatment options ordinarily not considered when tumor analysis is based on anatomical tumor type only.
G06F 19/18 - pour la génomique ou la protéomique fonctionnelle, p.ex. associations génotype-phénotype, déséquilibre de liaison, mutagénèse, génotypage ou annotation génomique, interactions protéines-protéines ou interactions protéines-acides nucléiques
G06F 19/10 - Bio-informatique, c. à d. procédés ou systèmes pour le traitement de données génétiques ou se rapportant aux protéines en biologie moléculaire informatique (procédés in silico de criblage de bibliothèques chimiques virtuelles C40B 30/02;procédés mathématiques ou in silicio de création de bibliothèques chimiques virtuelles C40B 50/02)
68.
HEALTHCARE TRANSACTION VALIDATION VIA BLOCKCHAIN PROOF-OF-WORK, SYSTEMS AND METHODS
Healthcare transaction validation systems and methods are presented. Healthcare transactions associated with a stakeholder are compiled into a chain of healthcare transaction blocks. The chain can be considered a chronicle of person's healthcare path through life. When a transaction is conducted, the corresponding healthcare parameters (e.g., inputs, outputs, clinical evidence, outcomes, etc.) are sent to one or more validation devices. The devices establish a validity of the transaction and generate a new block via a proof-of-work principle. Once the new block has been calculated it can be appended to the stakeholder's health care blockchain.
G06F 21/00 - Dispositions de sécurité pour protéger les calculateurs, leurs composants, les programmes ou les données contre une activité non autorisée
Techniques are provided in which a plurality of edges are detected within a digital image. An anchor point located along an edge of the plurality of edges is selected. An analysis grid associated with the anchor point is generated, the analysis grid including a plurality of cells. An anchor point normal vector comprising a normal vector of the edge at the anchor point is calculated. Edge pixel normal vectors comprising normal vectors of the edge at locations along the edge within the cells of the analysis grid are calculated. A histogram of similarity is generated for each of one or more cells of the analysis grid, each histogram of similarity being based on a similarity measure between each of the edge pixel normal vectors within a cell and the anchor point normal vector, and a descriptor is generated for the analysis grid based on the histograms of similarity.
A first fabric abstraction layer couples to a data link layer and a physical layer of a network fabric device. The network fabric device is connected to other network elements within a network via at least one network connection, such as a fiber optic connection. A second fabric abstraction layer couples to the data link layer and an application of the network device. The second fabric abstraction layer provides an application programming interface (API) to the application. The API allows the application to generate configuration instructions for configuring the at least one network connection. Upon receiving the configuration instructions generated by the application, the second abstraction layer sends the configuration instructions to the first abstraction layer via the data link layer. The first abstraction layer then configures the at least one network connection to transmit data according to the configuration instructions.
A method of allowing multiple devices to collaborate with content data is presented. The multiple devices can establish an interactive collaboration session via a multimedia protocol. The multimedia protocol allows users of the devices to share chat data, audio data, video data, or other types of data as they collaborate. Additionally, the users of the device can manipulate the content data in shared fashion by submitting one or more asynchronous commands. The commands are multiplexed into the multimedia protocol in a transparent manner. The devices within the group can extract the commands without disrupting the collaboration experience and then execute the commands to affect the content data.
G06F 17/00 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des fonctions spécifiques
72.
OBJECT RECOGNITION TRAIT ANALYSIS SYSTEMS AND METHODS
A system for analyzing scene traits in an object recognition ingestion ecosystem is presented. In some embodiment, a trait analysis engine analyzes a digital representation of a scene to derive one or more features. The features are compiled into sets of similar features with respect to a feature space. The engine attempts to discover which traits of the scene (e.g., temperature, lighting, gravity, etc.) can be used to distinguish the features for purposes of object recognition. When such distinguishing traits are found, an object recognition database is populated with object information, possibly indexed according to the similar features and their corresponding distinguishing traits.
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
73.
INVARIANT-BASED DIMENSIONAL REDUCTION OF OBJECT RECOGNITION FEATURES, SYSTEMS AND METHODS
A sensor data processing system and method is described. Contemplated systems and methods derive a first recognition trait of an object from a first data set that represents the object in a first environmental state. A second recognition trait of the object is then derived from a second data set that represents the object in a second environmental state. The sensor data processing systems and methods then identifies a mapping of elements of the first and second recognition traits in a new representation space. The mapping of elements satisfies a variance criterion for corresponding elements, which allows the mapping to be used for object recognition. The sensor data processing systems and methods described herein provide new object recognition techniques that are computationally efficient and can be performed in real-time by the mobile phone technology that is currently available.
An object recognition ingestion system is presented. The object ingestion system captures image data of objects, possibly in an uncontrolled setting. The image data is analyzed to determine if one or more a priori know canonical shape objects match the object represented in the image data. The canonical shape object also includes one or more reference PoVs indicating perspectives from which to analyze objects having the corresponding shape. An object ingestion engine combines the canonical shape object along with the image data to create a model of the object. The engine generates a desirable set of model PoVs from the reference PoVs, and then generates recognition descriptors from each of the model PoVs. The descriptors, image data, model PoVs, or other contextually relevant information are combined into key frame bundles having sufficient information to allow other computing devices to recognize the object at a later time.
G06K 9/68 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques utilisant des comparaisons successives des signaux images avec plusieurs références, p.ex. mémoire adressable
G06K 9/70 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques utilisant des comparaisons successives des signaux images avec plusieurs références, p.ex. mémoire adressable le choix de la référence suivante dépendant du résultat de la comparaison précédente
Systems and methods of generating a compact visual vocabulary are provided. Descriptor sets related to digital representations of objects are obtained, clustered and partitioned into cells of a descriptor space, and a representative descriptor and index are associated with each cell. Generated visual vocabularies could be stored in client-side devices and used to obtain content information related to objects of interest that are captured.
Edge-based recognition systems and methods are presented. Edges of the object are identified from the image data based on co-circularity of edgels, and edge-based descriptors are constructed based on the identified edges. The edge-based descriptors along with additional perception metrics are used to obtain a list of candidate objects matched with the edge-based descriptors. Through various filtering processes and verification processes, false positive candidate objects are further removed from the list to determine the final candidate object.
Apparatus, methods and systems of providing AR content are disclosed. Embodiments of the inventive subject matter can obtain an initial map of an area, derive views of interest, obtain AR content objects associated with the views of interest, establish experience clusters and generate a tile map tessellated based on the experience clusters. A user device could be configured to obtain and instantiate at least some of the AR content objects based on at least one of a location and a recognition.
A network fabric application coupled to a data link layer is provided with access to network elements in an optical fiber network. The network fabric application defines a network fabric configuration comprising at least a subset of the network elements, wherein the network fabric forms a multi-path communication network among the subset. The network fabric is configured to transmit data among networked devices in the network fabric along the multi- path communication network.
H04L 12/28 - Réseaux de données à commutation caractérisés par la configuration des liaisons, p.ex. réseaux locaux [LAN Local Area Networks] ou réseaux étendus [WAN Wide Area Networks]
Systems and methods of facilitating transactions related to targeted or customized commercial offerings based on derived sentiment states are provided. The system comprises a digital sensor configured to capture a digital representation of a scene; a sentiments database storing a plurality of sentiment states; a sentiments analysis engine; a commerce database storing a plurality of commercial offerings; and a commerce analysis engine. The sentiment states are derived from the digital representations such as images, videos and sound recordings.
A system capable of determining which recognition algorithms should be applied to regions of interest within digital representations is presented. A preprocessing module utilizes one or more feature identification algorithms to determine regions of interest based on feature density. The preprocessing modules leverages the feature density signature for each region to determine which of a plurality of diverse recognition modules should operate on the region of interest. A specific embodiment that focuses on structured documents is also presented. Further, the disclosed approach can be enhanced by addition of an object classifier that classifies types of objects found in the regions of interest.
Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
A system and method to accurately modify the function of a user's electronic device in response to the multiple aspects making up a user's evolving state of mind are presented. Persistent intent objects are generated to represent a user's state of mind and the relative importance of a particular state of mind to a user's instant attention. The intent objects can be related to situations or environments and could exist beyond any specific situations or environments. The collective effect of the intent objects can be used to customize the functions of a user device to match the user's state of mind extending beyond inferences drawn from an individual or instant set of circumstances.
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
The inventive subject matter provides apparatus, systems, and methods that improve on the pace of discovering new practical information based on large amounts of datasets collected. In most cases, anomalies from the datasets are automatically identified, flagged, and validated by a cross-validation engine. Only validated anomalies are then associated with a subject matter expert who is qualified to take action on the anomaly. In other words, the inventive subject matter bridges the gap between the overwhelming amount of scientific data which can now be harvested and the comparatively limited amount analytical resources available to extract practical information from the data. Practical information can be in the form of trends, patterns, maps, hypotheses, or predictions, for example, and such practical information has implications in medicine, in environmental sciences, entertainment, travel, shopping, social interactions, or other areas.
G06F 19/10 - Bio-informatique, c. à d. procédés ou systèmes pour le traitement de données génétiques ou se rapportant aux protéines en biologie moléculaire informatique (procédés in silico de criblage de bibliothèques chimiques virtuelles C40B 30/02;procédés mathématiques ou in silicio de création de bibliothèques chimiques virtuelles C40B 50/02)
G06F 19/28 - pour la programmation d'outils ou de systèmes de bases de données, p.ex. ontologies, intégration de données hétérogènes, entreposage de données ou architectures informatiques
84.
SYSTEMS, METHODS, AND COMPOSITIONS FOR VIRAL-ASSOCIATED TUMORS
Contemplated systems and methods employ chimeric reference sequences that include a plurality of viral genome sequences to identify/quantify integration and co-amplification events. Most typically, the viral genome sequences are organized in the chimeric reference sequences as single chromosomes and the chimeric reference sequences are in BAM format.
C12N 15/33 - Gènes codant pour des protéines virales
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G06F 19/10 - Bio-informatique, c. à d. procédés ou systèmes pour le traitement de données génétiques ou se rapportant aux protéines en biologie moléculaire informatique (procédés in silico de criblage de bibliothèques chimiques virtuelles C40B 30/02;procédés mathématiques ou in silicio de création de bibliothèques chimiques virtuelles C40B 50/02)
85.
CAMERA-TO-CAMERA INTERACTIONS, SYSTEMS AND METHODS
Systems and methods of delegating media capturing functionality from one device to another are presented. A first device configured with an object recognition engine captures a media representation of an environment and identifies an object within that environment. Then based on matched object traits from a database, the engine selects a delegation rules set, and delegates certain media capturing functionality to a second device according to the selected delegation rules set.
H04N 21/45 - Opérations de gestion réalisées par le client pour faciliter la réception de contenu ou l'interaction avec le contenu, ou pour l'administration des données liées à l'utilisateur final ou au dispositif client lui-même, p.ex. apprentissage des préféren
H04N 5/262 - Circuits de studio, p.ex. pour mélanger, commuter, changer le caractère de l'image, pour d'autres effets spéciaux
H04N 21/2381 - Adaptation du flux multiplexé à un réseau spécifique, p.ex. un réseau à protocole Internet [IP]
Apparatus, methods and systems of object recognition are disclosed. Embodiments of the inventive subject matter generates map-altered image data according to an object-specific metric map, derives a metric-based descriptor set by executing an image analysis algorithm on the map-altered image data, and retrieves digital content associated with a target object as a function of the metric-based descriptor set.
A power management system for a personal area fabric having a plurality of nodes is presented. The system implements power management functions at the fabric-level via fabric-level power profiles reflecting the aggregated power profiles from some or all of the nodes in the fabric. The fabric-level power profiles are used to trigger the implementation of fabric power configurations that cause the individual nodes to modify their operations in the interest of a fabric-level power management plan.
Engagement point management systems are presented. A consumer's behavior can be observed via one or more digital representations. The observed behaviors can be mapped to an expected behavior pattern constructed from individual engagement points. Each engagement point represents a possible communication channel between a third party content provider and the consumer. When a consumer is found within an engagement point, context information associated with the consumer can be matched with contexts of the third party's content.
A virtual assistant ecosystem is presented. One can instantiate or construct a customized virtual assistant when needed by capturing a digital representation of one or more objects. A virtual assistant engine analyzes the digital representation to determine the nature or type of the objects present. The engine further obtains attributes for a desirable assistant based on the type of objects. Once the attributes are compiled the engine can then create the specific type of assistant required by the circumstances.
Link association analysis systems are presented. Disclosed systems are configured to analyze links created by users and to determine possible reasons underpinning why a user would create such a link. The system derives such reasons by analyzing the context within which the link was created and to which the link points, and then presents the reasons as a data object to users for feedback. The system can be made to be self-refining by collecting survey data regarding its accuracy, so that the more users interact with the system, the more accurate the system is at deriving reasons for link creation.
G06F 17/00 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des fonctions spécifiques
G06F 15/16 - Associations de plusieurs calculateurs numériques comportant chacun au moins une unité arithmétique, une unité programme et un registre, p.ex. pour le traitement simultané de plusieurs programmes
Interaction-based ecosystems are presented. Interaction analysis engine analyze media content to derive a set of media features. The engine can then identify one or more interaction objects (e.g., transactions, searches, game play, etc.) based on the set of media features. Relevant interaction objects can then be instantiated as persistent available or active points of interaction readily accessed by a consumer. The consumer need only capture a digital representation of the content via a user device, a smart phone for example. A second set of media features can be derived from the digital representation and the second set of media features can then be used to find the instantiated interactions.
A number of sets of methods, systems, and apparatuses applicable to transactions are disclosed. One set includes transaction systems configured to reconcile a transaction among multiple provider accounts or user accounts via derived object attributes and reconciliation matrices. Another set includes methods of reconciling payment of a coupon. Another set includes transaction apparatuses configured to derive object attributes from digital representations to identify purchasable items. Still another set includes methods of mitigating risk of transaction fraud.
Multimodal story management systems and methods are described having a story server capable of delivering synchronized content streams of a story to multiple devices of a user, or even to multiple users. The story server can be coupled to a story management engine that is configured to present the first story stream to a first media device, and automatically present the second story stream to a second media device as a function of a triggering event contained within the first story stream.
Story management systems and methods are described that allow a user to use a first user device to sample a media stream and interact with a story related to the media stream sample. The sample or related data can be analyzed by an analysis engine coupled to a story database to generate a set of characteristics associated with the sample. A story engine can then identify a story in the story database as a function of the set of characteristics and then automatically present the identified story to the user.
G06F 17/00 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des fonctions spécifiques
G06F 15/16 - Associations de plusieurs calculateurs numériques comportant chacun au moins une unité arithmétique, une unité programme et un registre, p.ex. pour le traitement simultané de plusieurs programmes
Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
Systems and methods of constructing and managing virtual planograms are presented. Contemplated systems allow for construction of a virtual planogram, which can be used to present consumers virtual inventory items as being available for purchase via a display device. The display device can include an electronic billboard within an establishment, a mall for example, or include a user's smart device, a cell phone or tablet for example.
The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.
The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
Apparatus, systems and methods for pre-processing, analyzing, and storing genomic data through a saclable, distributed analysis system across a network are presented. One aspect of this invention includes a genomic analysis system to process genomic sequence data from many patients in parallel by using a sequencing device, an analysis network, and plurality of analysis nodes connected through the analysis network. The sequencing device interface can be configured to obtain sequencing data from many sequencing devices in parallel, from image recognition programs of devices, and/or one or more databases storing sequence information.
Synergistic toys and apparatus are presented. Toys are able to communicate with each other, preferably through a wireless interface. The toys can include native skills; executable instructions, representing features of the toy. When a first toy is placed within proximity of another toy, the first toy can acquire new non-native skills from the second toy or vice versa. Thus, toys can interact with one or more other toys to give rise to an enriched interactive feature set.
brevets
